IL17A and psoriasis: Secukinumab, a fully human monoclonal antibody (IgG1) targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine central to the pathogenesis of systemic inflammatory diseases such as psoriasis, represents a significant advancement in therapy [3].